Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018)

Savara's (SVRA) quarterly Asset Writedowns and Impairment came in at $21.7 million in Q1 2018, up 21037.15% on a QoQ basis from $102625.0 in Q4 2012.

Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018) Analysis & Trends

Savara (SVRA) has 2 years of Asset Writedowns and Impairment data on file, last reported at $21.7 million in Q1 2018.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $21.7 million in Q1 2018; TTM through Dec 2018 was $21.7 million, a N/A change from a year earlier, with the FY2018 full-year figure at $21.7 million, changed N/A from the prior year.
Asset Writedowns and Impairment for Q1 2018 stood at $21.7 million, up from $102625.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for SVRA reached as high as $21.7 million in Q1 2018 and fell as low as $21.7 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,200.25 Bn	66,199.96 Bn	-
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	471.75 Bn	466.96 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.94 Bn	114.69 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.87 Bn	61.12 Bn	3.31 Bn
7	Belite Bio	62.43 Bn	62.43 Bn	-
8	Argenx Se	55.86 Bn	50.68 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn
10	Savara	1.39 Bn	1.39 Bn	-

Download Data